Delving into the Latest Updates on Korea University of Science & Technology with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

蛋白水解靶向嵌合体（PROTAC）	1

排名前五的靶点	数量

BRD4(溴结构域蛋白-4)	1

关联

12

项与 Korea University of Science & Technology 相关的药物

TD-428

靶点

BRD4

作用机制

BRD4降解剂 [+1]

在研机构

Korea University of Science & Technology [+1]

原研机构

Korea University of Science & Technology [+1]

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

TD-230

靶点

BRD4

作用机制

BRD4降解剂

在研机构-

原研机构

Korea Research Institute of Bioscience & Biotechnology [+1]

在研适应症-

非在研适应症

肿瘤

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

TD-760

靶点

CRBN

作用机制

CRBN抑制剂

在研机构-

原研机构

Korea Research Institute of Bioscience & Biotechnology

在研适应症-

非在研适应症-

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Korea University of Science & Technology 相关的临床结果

登录后查看更多信息

0 项与 Korea University of Science & Technology 相关的专利（医药）

登录后查看更多信息

6,290

项与 Korea University of Science & Technology 相关的文献（医药）

2025-07-01·Genes & Diseases

Proteomic profiling of exosomes leads to the identification of a candidate biomarker for prostate cancer progression

Article

作者: Kook, Hae Un ; Ahn, Soon-Cheol ; Kim, Won-Kyeong ; Lee, Ah Reum ; Ko, Myunggon ; Park, Chan Young ; Shin, Hyeon-Bin ; Jung, Inkyung ; Yoo, Youngbum ; Yeon, MyeongHoon ; Seo, Young-Kyo

2025-07-01·European Journal of Medicinal Chemistry

Discovery of a novel molecular glue degrader targeting GSPT1/2 with a non-IMiD-based CRBN binder

Article

作者: Lee, Joo Youn ; Lee, Gaseul ; Kim, Jung-Ae ; Hwang, Jong Yeon ; Kim, Jeong-Hoon ; Moon, Jeong Hee ; Cho, Jin Hwa ; Takwale, Akshay D ; Yu, Namsik ; Cho, Yong Hee ; Kim, Yong Hyo ; Lee, Ji-Eun ; Park, Seulki

Targeting undruggable proteins by inducing proximity between E3 ligase and their substrates has emerged as an innovative strategy for tackling challenging diseases. In this study, we identified a novel GSPT1 degrader, 4a (KMG-1068), through screening of our in-house small molecule library. Treatment with 4a demonstrated significant anti-proliferative activity across multiple cell lines, which was diminished by co-treatment with MLN4924, suggesting the involvement of the Cullin-containing complex. Quantitative proteomic analysis indicated that 4a predominantly induces the degradation of GSPT1/2. We further validated that 4a-mediated GSPT1/2 degradation is dependent on both CUL4 and CRBN. Moreover, 4a forms a ternary complex with CRBN and GSPT1/2, albeit with weaker binding affinity compared to reported GSPT1 molecular glues. BRET assays and competition assays with pomalidomide demonstrated that 4a binds to the C-terminal IMiD binding site of CRBN, leading to the degradation of GSPT1. Despite lacking the characteristic glutarimide moiety present in other CRBN-based molecular glue degraders, 4a interacts effectively with the IMiD binding site of CRBN. Structural characterization through analog synthesis further underscored the importance of specific structural features for CRBN engagement, GSPT1/2 degradation, and anti-proliferative effects, establishing 4a as a promising novel GSPT1/2 degrader with significant therapeutic potential.

2025-06-01·Materials Today Bio

Micro-fragmented collagen hydrogel wound dressing: Enhanced porosity facilitates elevated stem cell survival and paracrine effects for accelerated wound maturation

Article

作者: Hong, Changgi ; Lee, Youngseop ; Kim, Jong-Wan ; Kim, Dongwoo ; Kim, Jeongmin ; Lee, Kangwon ; Chung, Haeun ; Kim, Sang-Heon

Human Adipose-derived stem cells (hADSCs), known for their mesenchymal stem cell properties, including multilineage differentiation and self-renewal, hold significant promise for chronic wound regeneration. Typically, hADSCs are utilized in cellular aggregates or hydrogels to enhance therapeutic efficacy. However, limitations such as reduced cell viability, inadequate mass transfer rates, and diminished paracrine effects hinder their clinical applications. This study explores an innovative approach by encapsulating hADSCs within a collagen/hyaluronic acid micro-fragmented collagen hydrogel wound dressing (MCWD). The resulting micro-fragmented collagen hydrogel-hADSC composite created through the integration of micro-sized hydrogel units and cells demonstrated markedly improved cell viability and activity, as well as superior therapeutic outcomes compared to conventional cell aggregates (CA) and collagen hydrogel wound dressings (CWD). In vitro assessments showed that the highly porous structure of MCWD promotes better mass transfer and enhances the viability and cytokine production of hADSCs associated with the paracrine effect. In vivo experiments further validated the effectiveness of the MCWD, revealing significant enhancements in cell proliferation, skin thickness restoration, collagen maturation, and blood vessel formation. These findings underscore the potential of MCWD as an advanced solution for wound healing applications.

100 项与 Korea University of Science & Technology 相关的药物交易

登录后查看更多信息

100 项与 Korea University of Science & Technology 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月09日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

11

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

TD-428 ( BRD4 )	肿瘤更多	临床前
TD-106 ( CRBN )	多发性骨髓瘤更多	无进展
TD-156 ( CRBN )	-	无进展
TD-165 ( CRBN )	-	无进展
TD-188 ( BRD4 )	肿瘤更多	无进展